Figure 5.

Rosuvastatin inhibited astrocyte activation. (A) Representative images of DAPI and glial fibrillary acidic protein (GFAP) staining, as described above. Scale bars: 50 μm. (B) The quantified GFAP immunofluorescence intensity at 24 h after reperfusion; the results were normalized to DAPI. (C) Transmission electron microscopy image showing the ultrastructure of astrocytes. Scale bar: 200 nm. (D) GFAP expression levels, as determined by western blotting (n = 6 in each group); the results were normalized to β-actin. The values were expressed as the mean ± SEM (a–d for the SHAM, HT, HT+LRO and HT+HRO groups, respectively, as shown in Figure 1). *P < 0.05 and ***P < 0.001 vs. the SHAM group,^#P < 0.05 and ^###P < 0.001 vs. the HT group, ^&P < 0.05 vs. the normal-dose rosuvastatin-treated group.